-
公开(公告)号：US20070042940A1
公开(公告)日：2007-02-22
申请号：US11005467
申请日：2004-12-06
IPC分类号： A61K38/14 , A61K31/7076 , A61K31/7072 , A61K31/522 , A61K31/513
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
公开(公告)号：US20070042939A1
公开(公告)日：2007-02-22
申请号：US11005445
申请日：2004-12-06
IPC分类号： A61K31/7076 , A61K38/14 , C07J17/00 , C07H19/16
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
公开(公告)号：US20070027066A1
公开(公告)日：2007-02-01
申请号：US11005470
申请日：2004-12-06
IPC分类号： A61K38/16 , C07H19/04 , C07H19/22 , C07H19/048 , A61K31/675 , A61K31/7076 , A61K31/7072
CPC分类号： C07H19/16 , A61K9/20 , A61K9/48 , A61K31/675 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K38/21 , A61K38/212 , A61K45/06 , A61K47/60 , C07H19/00 , C07H19/04 , C07H19/048 , C07H19/056 , C07H19/06 , C07H19/22 , A61K2300/00
摘要： 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
公开(公告)号：US20070015905A1
公开(公告)日：2007-01-18
申请号：US10609298
申请日：2003-06-27
CPC分类号： C07K9/003 , A61K31/7068 , A61K31/7072 , A61K38/00 , A61K45/06 , C07H19/06 , C07H19/067 , A61K2300/00
摘要： 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
-
-
-
搜索结果
24 条记录 (耗时 0.031 秒)
